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Background: Lung cancer mortality in men has been declining since the late 1980s in most European
countries. In women, although rates are still appreciably lower than those for men, steady upward
trends have been observed in most countries. To quantify the current and future lung cancer epidemic
in European women, trends in lung cancer mortality in women over the last four decades were
analyzed, with specific focus on the young.
Patients and methods: Age-standardized (world standard) lung cancer mortality rates per 100 000
women—at all ages, and truncated 35–64 and 20–44 years—were derived from the WHO for the
European Union (EU) as a whole and for 33 separate European countries. Joinpoint regression analysis
was used to identify points where a significant change in trends occurred.
Results: In the EU overall, female lung cancer mortality rates rose by 23.8% between 1980–1981 and
1990–1991 (from 7.8 to 9.6/100 000), and by 16.1% thereafter, to reach the value of 11.2/100 000 in
2000–2001. Increases were smaller in the last decade in several countries. Only in England and Wales,
Latvia, Lithuania, Russia and Ukraine did female lung cancer mortality show a decrease over the
last decade. In several European countries, a decline in lung cancer mortality in young women (20–44
years) was observed over the last decade.
Conclusions: Although female lung cancer mortality is still increasing in most European countries, the
more favorable trends in young women over recent calendar years suggest that if effective interventions
to control tobacco smoking in women are implemented, the lung cancer epidemic in European women
will not reach the levels observed in the USA.
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Introduction
Lung cancer mortality in men has been declining since the late
1980s in most European countries. The overall fall was over
13% (from 55.4 to 46.7/100 000 men, world standard) between
1988 and 2000 in the 25 countries of the European Union (EU)
[1]. Downward trends were observed also in the Russian Feder-
ation, and central and eastern European countries, characterized
by exceedingly high rates in the early 1990s [2–4]. The only
exceptions were Portugal and Romania, where male lung cancer
mortality was still increasing.
In women, lung cancer mortality rates in most Europe are still
appreciably lower than those for men, but the pattern of trends is
largely different, since steady upward trends have been observed
in most countries, reaching extremely high levels (20 to 25/
100 000 at all ages) in Denmark, Iceland, Ireland and the
UK [3–7]. In most other European countries, female lung can-
cer mortality rates are still below 10/100 000, substantially
lower than in North America [8, 9]. A clearer understanding
of the ongoing lung cancer epidemic among European women
requires detailed analysis of trends in separate age groups.
We present therefore a comprehensive analysis of trends
in lung cancer mortality in European women over the last
four decades, with specific focus on the young, who are of
specific interest to shed light on the most likely future trends
[10, 11].
Patients and methods
Official death certification numbers for lung cancer for 33 European coun-
tries (including the Russian Federation, but excluding a few small countries
such as Andorra and Liechtenstein) for the period 1965–2001 were derived
from the WHO database as available on electronic support [12]. As well
as the UK as a whole, data are also presented separately for England and
Wales, Scotland and Northern Ireland. Data for the Russian Federation and
other Republics included in the former Soviet Union have been available in
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the WHO database from the early 1980s onwards. For Albania, data are
available only since 1989, for Belgium up to 1997, and for Denmark, France
and The Netherlands up to 2000.
The EU was defined as the 25 member states as in May 2004 (i.e. Austria,
Belgium, the Czech Republic, Cyprus, Denmark, Estonia, Finland, France,
Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg,
Malta, The Netherlands, Poland, Portugal, Slovakia, Slovenia, Spain,
Sweden, UK). Data for Cyprus were not available. During the calendar
period considered (1965–2001) three different revisions of the International
Classification of Diseases (ICD) were used [13–15]. Classification of cancer
deaths was recoded, for all calendar periods and countries, according to the
Ninth Revision of the ICD [14].
Estimates of the resident population, generally based on official censuses,
were obtained from the same WHO database [12]. From the matrices of
certified deaths and resident populations, age-specific rates for each 5-year
age group and calendar year were computed. Age-standardized rates per
100 000 women—at all ages, and truncated 35–64 years and 20–44
years—were computed using the direct method, and based on the world
standard population [16].
Joinpoint regression analysis was performed using the joinpoint software
from the Surveillance Research Program of the US National Cancer In-
stitute [17]. This analysis allows us to identify points where a significant
change in the linear slope of the trend occurred [18]. In joinpoint analysis,
the best fitting points (the ‘joinpoints’) are chosen where the rate changes
significantly. The analysis starts with the minimum number of joinpoints
(e.g. zero joinpoints, which is a straight line), and tests whether one or more
joinpoints (up to three) are significant and must be added to the model. In
the final model, each joinpoint (if any) indicates a significant change in the
slope. The estimated annual percent change (EAPC) is then computed for
each of those trends by fitting a regression line to the natural logarithm of
the rates using calendar year as a regressor variable [i.e. given y = a + bx,
where y = ln(rate) and x = calendar year, the EAPC is estimated as:
100 * (eb  1)].
Results
Table 1 gives the age-adjusted mortality rates from lung cancer
in women (at all ages, and truncated 35–64 and 20–44 years) for
33 European countries in 1980–1981, 1990–1991 and 2000–
2001, and the corresponding percentage changes between the
three periods. In the EU as a whole, female lung cancer mortal-
ity rose by 23.8% between 1980–1981 and 1990–1991 (from
7.8 to 9.6/100 000). A further increase, though smaller
(16.1%), was observed afterward, to reach the rate of 11.2/
100 000 in 2000–01. Steady upward rates between 1980–1981
and 1990–1991 were observed in most European countries, with
the highest rises found in some countries of northern, central and
eastern Europe, including Denmark, Germany, Hungary, Nor-
way and Poland. Smaller increases were found in several coun-
tries, with the exception of France and Switzerland, which
showed larger increases between 1980–1981 and 1990–1991.
Only in Latvia, Lithuania, England and Wales, the Russian Fed-
eration, and Ukraine did female lung cancer mortality show
a decrease between 1990 and 2001. In England and Wales,
however, lung cancer rates in 2001 were still 20/100 000.
Lung cancer mortality in EU middle-aged women increased
by 17.2% between 1980–1981 and 1990–1991 (from 7.8 to
9.6/100 000), and by a further 21.1% thereafter, to reach a value
of 17.9/100 000 in 2000–01. In most European countries, the
changes in truncated rates between 1980–1981 and the 1990s
were similar to those for the overall ones, the only exceptions
being Ireland, the Russian Federation, Ukraine, and England
and Wales, which already showed declines in rates. Between
1990–1991 and 2000–2001 rates in middle-aged women showed
a decline in a few European countries, including Britain,
Denmark, Ireland, the Russian Federation and Ukraine. In
France and Spain, however, steady upward trends were
observed in this period.
We also considered trends in young women (20–44 years)
from various European countries in 1980–1981, 1990–1991
and 2000–2001 (Table 1). In the EU, lung cancer mortality rates
per 100 000 in young women were 1.1 in 1980–1981, 1.5 in
1990–1991 and 1.7 in 2000–2001, corresponding to percentage
increases of 35.5 and 11.4% in the two periods, respectively. In
various European countries, however, a decline in lung cancer
mortality in young women was observed over the last decade.
Figure 1 shows trends in female lung cancer mortality at all
ages and truncated at 35–64 years for selected European coun-
tries between 1965 and 2001. A steady upward trend in overall
rates was observed in several European countries over the four
decades considered. A levelling of lung cancer mortality was
observed in Denmark, Iceland (since the late 1990s), Ireland
and the UK (since the late 1980s). In these countries, however,
rates had steeply increased in the previous decades, when
they reached the highest values on a European scale. Trends
in middle-aged women follow similar, though more pronounced,
patterns than those for all women. Thus, the rises were stronger
than those in overall rates in most countries with increasing
mortality from lung cancer. In countries where overall lung
cancer mortality tended to level off in more recent years (i.e.
Denmark, Iceland, Ireland and the UK), truncated rates showed
declining trends.
Lung cancer mortality trends in young women (20–44 years)
over the period 1965–2001 in selected European countries are
shown in Figure 2. Although less clear than overall and 35–64
years trends due to smaller numbers of deaths, the trends over
recent calendar periods appeared to be more favorable than
those in all-age and middle-aged women in most European
countries. Thus, in several European countries (including
Austria, Hungary, Italy, The Netherlands, Poland, Sweden
and Switzerland), rates tended to decline in young women in
the last few years. Steady long-term declines in rates were ob-
served in Ireland and the UK since the late 1960s. Lung cancer
mortality rates in young women were still consistently increas-
ing in France and Spain up to more recent calendar years.
The main findings from jointpoint regression analysis for fe-
male lung cancer mortality (at all ages, and truncated at 35–64
and 20–44 years) over the period 1965–2001 in the EU overall
are given in Table 2 and Figure 3. At all ages, female lung cancer
rates rose by 1.5% per year between 1965 and 1971, by 2.6%
between 1972 and 1987, and by 1.4% thereafter. In middle-aged
women, the rise was 2.1% per year until 1983, 1.4% between
1984 and 1997, and 2.9% thereafter. In young women, after a
decrease between 1965 and 1969 (0.8% per year), rates rose
by 2.8% per year between 1970 and 1997, and subsequently
declined by 3.6% over the last 4 years.
1598
Table 1. Age-adjusted (world population) death certification rates per 100 000 for lung cancer in women (all ages, truncated 35–64 years and 20–44 years) in selected European countries and in
the European Union, in the years 1980–81, 1990–91 and 2000–01
Country All ages Age 35–64 years Age 20–44 years
Death rate/100 000 Percent change Death rate/100 000 Percent change Death rate/100 000 Percent change
1980–81 1990–91 2000–01 1990–91/
1980–81
2000–01/
1990–91
1980–81 1990–91 2000–01 1990–91/
1980–81
2000–01/
1990–91
1980–81 1990–91 2000–01 1990–91/
1980–81
2000–01/
1990–91
Albania – 5.07a 6.72 – 32.50 – 7.39a 8.15 – 10.3 – 1.31a 1.39 – 6.1
Austria 7.31 9.19 11.11 25.7 20.90 10.19 14.21 19.22 39.5 35.3 0.75 2.09 1.71 178.7 18.2
Belgium 6.48 8.48 10.02b 30.9 18.20 10.47 15.09 16.64b 44.1 10.3 1.14 1.89 1.87b 65.8 1.1
Bulgaria 5.69 6.36 6.38 11.8 0.30 8.88 10.15 11.3 14.3 11.3 1.32 1.74 1.61 31.8 7.5
Croatia – 8.19 10.76 – 31.40 – 13.92 16.97 – 21.9 – 2.02 1.91 – 5.4
Czech Republic – 9.91 12.75 – 28.70 – 16.88 20.58 – 21.9 – 1.57 1.15 – 26.8
Denmark 15.35 24.88 27.44c 62.1 10.3 29.31 44.14 38.96c 50.6 11.7 2.27 2.13 2.48c 6.3 16.4
Estonia 7.53d 7.57 7.49 0.5 1.1 9.23d 11.73 10.64 27.1 9.3 0.72d 1.11 1.05 54.2 5.4
Finland 5.99 6.85 7.86 14.4 14.7 8.49 8.70 10.52 2.5 20.9 0.66 0.75 0.71 13.6 5.3
France 3.84 5.19 7.31c 35.2 40.9 6.07 8.41 13.43c 38.6 59.7 0.61 1.08 2.12c 77.1 96.3
Germany 5.65 8.10 10.75 43.4 32.7 8.62 12.94 18.21 50.1 40.7 0.82 1.41 1.64 72.0 16.3
Greece 6.03 7.22 7.56 19.7 4.7 9.33 11.51 10.99 23.4 4.5 1.54 1.43 1.16 7.1 18.9
Hungary 10.07 15.73 21.25 56.2 35.1 16.23 28.15 42.06 73.4 49.4 1.90 4.89 4.96 157.4 1.4
Iceland 23.46 23.44 26.68 0.1 13.8 32.93 39.21 39.32 19.1 0.3
Ireland 15.70 17.74 17.80 13.0 0.3 26.30 25.60 19.33 2.7 24.5 2.41 0.94 1.34 61.0 42.6
Italy 6.05 7.32 8.38 21.0 14.5 9.50 10.62 12.17 11.8 14.6 0.92 1.11 1.24 20.7 11.7
Latvia 5.7d 6.73 6.06 18.1 10.0 9.85d 9.63 8.65 2.2 10.2 0.72d 0.69 0.73 4.2 5.8
Lithuania 4.99d 6.09 5.34 22.0 12.3 8.99d 9.33 6.94 3.8 25.6 0.33d 0.96 0.75 190.9 21.9
Luxembourg 6.69 9.13 10.94 36.5 19.8 10.42 15.51 19.99 48.9 28.9
Malta 5.54 2.82 7.13 49.1 152.8 5.88 3.38 9.85 42.5 191.4
The Netherlands 6.29 10.53 16.87c 67.4 60.2 11.11 20.16 30.72c 81.5 52.4 1.28 2.04 2.63c 59.4 28.9
Norway 5.81 10.81 16.32 86.1 51.0 10.35 19.03 25.53 83.7 34.2 0.86 1.34 1.67 55.8 24.6
Poland 7.05 10.05 12.69 42.6 26.3 12.46 17.6 22.75 41.3 29.3 1.20 1.89 1.81 57.5 4.2
Portugal 3.73 4.53 4.79 21.5 5.70 5.91 6.72 7.43 13.7 10.6 1.13 1.3 1.18 15.0 9.2
Romania 6.22 6.49 7.89 4.34 21.3 11.38 11.79 13.53 3.6 14.8 1.76 1.64 1.77 6.8 7.9
Russian Federation 6.53 7.30 5.95 11.8 18.5 11.08 10.99 8.86 0.8 19.4 1.31 1.2 1.10 8.4 8.3
Slovakia – 7.33e 7.61 – 3.8 – 11.99e 12.02 – 0.3 – 1.42e 1.43 – 0.7
Slovenia – 8.31 10.83 – 30.3 – 14.36 18.42 28.3 28.3 – 0.73 2.20 – 201.4
Spain 3.83 3.61 4.71 5.7 30.5 5.53 5.3 8.77 4.2 65.5 0.91 1.15 1.67 26.4 45.2
Sweden 7.67 10.35 13.84 34.9 33.7 13.05 17.91 22.30 37.2 24.5 1.32 1.67 1.06 26.5 36.5
1
5
9
9
Discussion
The present comprehensive analysis of female lung cancer mor-
tality in Europe indicates and quantifies a steady increase in
rates in women from most European countries over the last
few decades. In the EU overall, the rates increased from 5.53/
100 000 in 1965 to 11.16 in 2001 at all ages, and from 9.15 to
17.88 in middle-aged women. However, as in the USA [19],
a gradual slowing in the rate of increase has been observed over
recent years. According to the jointpoint regression analysis,
female lung cancer mortality in the EU increased by 2.6% per
year between the early 1970s and the late 1980s, and by 1.4%
thereafter.
Rises in female lung cancer rates were consistently observed
in several European countries, although the degree of the
increase varied between countries. Thus, particularly sharp
increases were observed in some northern, central and eastern
countries such as Denmark, Germany, Hungary and Poland. In
England and Wales, Ireland and Iceland [5], where rises were
earlier and mortality rates were higher, a levelling off in overall
rates—and a decline in middle-aged and young women—was
observed in more recent years.
The different patterns of female lung cancer mortality reflect
the different prevalence of tobacco smoking in women from
various European countries, which in turn can help in interpret-
ing recent and future trends in lung cancer mortality. The lag in
the temporal trend of lung cancer mortality rates in women
compared with men also reflects historical differences in ciga-
rette smoking between men and women. In some northern coun-
tries such as Belgium, Denmark, Sweden and The Netherlands,
where the estimated smoking prevalence in women has fallen
recently, a slowing of lung cancer mortality rates can be
expected in the future, as already observed in the UK [20–22].
The female lung cancer epidemic seems to be still in its early
phases in countries like Austria, Spain and France, where smok-
ing prevalence in women has been rapidly increasing in the
1990s [21, 22]. Among countries of central and eastern Europe,
Hungary is the only country where a steady increase in smoking
prevalence has been observed since the 1960s [23]. Conversely,
the prevalence of tobacco smoking among Russian, as well as
Ukrainian, women has remained relatively low in the last dec-
ades (i.e. 10–15%) [24]. The declining trends observed in the
Russian Federation should be taken with caution since they are
also influenced by effects in earlier cohorts, owing to the limited
availability of cigarettes in generations who were teenagers in
the post-war period [25].
A major finding of the present analysis is the more favorable
lung cancer mortality trends in young women, particularly in
countries where a peak has already been reached, suggesting
that overall trends are likely to be more favorable in the future.
Trends for young adults are in fact an early indicator of the
recent and potential future impact of changes in the prevalence
of risk factors—notably tobacco smoking—on cancer rates [11,
26]. Also in the USA, the effect of decreasing the prevalence of
smoking was seen first in young adults [27–29]. We chose to use
the age-standardized rates at age 20–44 years as a measure of
lung cancer trends in the young, as suggested by Doll in theT
a
b
le
1
.
(C
o
n
ti
n
u
ed
)
C
o
u
n
tr
y
A
ll
ag
es
A
g
e
3
5
–
64
y
ea
rs
A
g
e
2
0
–
44
y
ea
rs
D
ea
th
ra
te
/1
0
0
0
0
0
P
er
ce
n
t
ch
an
g
e
D
ea
th
ra
te
/1
0
0
0
0
0
P
er
ce
n
t
ch
an
g
e
D
ea
th
ra
te
/1
0
0
0
0
0
P
er
ce
n
t
ch
an
g
e
1
9
8
0–
8
1
1
9
9
0–
9
1
2
0
0
0
–
0
1
1
9
9
0–
9
1
/
1
9
8
0–
8
1
2
0
0
0–
0
1
/
1
9
9
0–
9
1
1
9
8
0
–
8
1
1
9
9
0–
9
1
2
0
0
0–
0
1
1
9
9
0
–
9
1/
1
9
8
0
–
8
1
2
0
0
0
–
0
1/
1
9
9
0
–
9
1
1
9
8
0
–
8
1
1
9
9
0
–
9
1
2
0
0
0–
0
1
1
9
9
0–
9
1
/
1
9
8
0–
8
1
2
0
0
0–
0
1
/
1
9
9
0–
9
1
S
w
it
ze
rl
an
d
5
.4
3
7
.5
0
1
0
.7
0
3
8
.1
4
2
.7
9
.1
5
1
2
.8
4
1
8
.3
3
4
0
.3
4
2
.8
1
.2
3
1
.6
2
1
.2
5
3
1
.7
2
2
.8
U
k
ra
in
e
6
.5
5d
7
.3
5
5
.5
1
1
2
.2
2
5
.0
1
1
.7
d
1
1
.2
3
8
.9
7
4
.0
2
0
.1
1
.6
1
d
1
.4
2
1
.3
1
1
1
.8
7
.8
U
K
1
7
.8
2
2
1
.0
6
1
9
.7
5
1
8
.2
6
.2
3
0
.2
4
2
9
.3
9
2
4
.7
4
2
.8
1
5
.8
1
.7
8
1
.5
6
1
.1
9
1
2
.4
2
3
.7
U
K
,
E
n
g
la
n
d
/W
al
es
1
7
.4
0
2
0
.3
7
1
8
.8
3
1
7
.1
7
.6
2
9
.2
7
2
8
.2
7
2
3
.6
7
3
.4
1
6
.3
1
.7
1
1
.4
8
1
.1
3
1
3
.5
2
3
.7
U
K
,
N
o
rt
h
er
n
Ir
el
an
d
1
4
.1
6
1
7
.1
4
1
9
.6
6
2
1
.1
1
4
.7
2
5
.7
0
2
4
.8
6
2
4
.0
8
3
.3
3
.1
1
.0
4
1
.4
2
0
.8
7
3
6
.5
3
8
.7
U
K
,
S
co
tl
an
d
2
2
.8
0
2
8
.8
4
2
8
.9
2
2
6
.5
0
.3
4
0
.8
6
4
1
.2
3
5
.6
0
.8
1
3
.6
2
.6
2
2
.4
0
1
.8
4
8
.4
2
3
.3
E
u
ro
pe
an
U
n
io
n
7
.7
6
9
.6
1
1
1
.1
6
2
3
.8
1
6
.1
1
2
.6
1
1
4
.7
8
1
7
.9
1
7
.2
2
1
.1
1
.1
0
1
.4
9
1
.6
6
3
5
.5
1
1
.4
a
D
at
a
re
fe
r
to
th
e
y
ea
rs
1
9
8
8–
1
9
89
.
b
D
at
a
re
fe
r
to
th
e
y
ea
rs
1
9
9
6–
1
9
9
7
.
c
D
at
a
re
fe
r
to
th
e
y
ea
r
2
0
0
0.
d
D
at
a
re
fe
r
to
th
e
y
ea
r
1
9
8
1.
e
D
at
a
re
fe
r
to
th
e
y
ea
rs
1
9
9
2–
1
9
93
.
1600
Figure 1. Trends in age-standardized (world population) death certification rates per 100 000 for lung cancer in women (all ages, and age 35 to 64 years)
in selected European countries, 1965–2001. All ages, solid lines; truncated at 35–64 years, dotted line.
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Figure 2. Trends in age-standardized (world population) death certification rates per 100 000 for lung cancer in women aged 20–44 years in
selected European countries, 1965–2001.
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1990s [11], and adopted for instance by Polednak [29] to ana-
lyze lung cancer incidence trends in black and white young
adults in the USA. These rates are heavily influenced by the last
quinquennia of age, since over 90% of all lung cancer deaths at
age 20–44 years occur at 35–44 years, and over 70% at 40–44
years (median age at death 42 years). Other measures of lung
cancer rates in the young have been suggested, such as using the
age group 30–39 years [28]. These are, however, on average at
a younger age (median age at death 38 years), and are based
on smaller absolute numbers. Therefore, this would be a major
problem for smaller countries.
Thus, since EU female lung cancer rates at age 20–44 years
have leveled off in the late 1990s at values 50% lower than
those of their male counterparts, it is likely that overall lung
cancer rates in EU women will continue to increase for some
years, to then stabilize at a value 15/100 000 between 2015
and 2020. Any more precise estimate is, however, hampered by
major uncertainties in the prevalence of smoking in women over
the next few years, and mostly by the role of stopping smoking
over the next decades [30]. In the presence of effective inter-
vention to reduce smoking among European women, the peak
rate may be lower. Assuming a constant 1.4% rise per year
between 2000 and 2015, the rate would approach 14/100 000.
With a 1% rise, it would remain 13/100 000.
In the interpretation of the present results it is important to
consider problems related to random variation, which are clearly
greater in relation to smaller populations. Secondly, and more
complex, there are problems of death certification reliability and
validity in various countries [31, 32]. In general, for lung cancer,
death certification is sufficiently reliable to permit meaningful
inference on trends for most European countries. Furthermore,
trends in the young are less likely to be affected by certification
problems. Some under-recording of cancer deaths was reported
for the Russian Federation in the late 1980s and 1990s, due to
a fall in precision of coding of causes of death. This was, how-
ever, mainly restricted to the elderly living in rural areas [33],
and should therefore not have materially influenced rates at
younger ages. Moreover, no major changes in lung cancer treat-
ments and survival have occurred in the last decades that could
have materially influenced mortality trends [34].
Overall, age-standardized female lung cancer mortality across
Europe is still much lower than in the USA, where lung cancer
has become the leading cause of cancer death among women,
with a rate of 24/100 000 in the year 2000 [8,9]. Only a few
European countries have female lung cancer rates comparable to
those of the USA, but there a peak seems to have been reached.
In most other European countries, the lower extent of more re-
cent increases compared with those of the past, and the more
favorable trends in young women, suggest that female lung
cancer mortality rates will probably not reach the high levels
observed in the USA [5, 8]. Effective interventions to control
and reduce tobacco smoking in women should be implemented
to avoid a major lung cancer epidemic in European women in
the near future.
Table 2. Age-standardised (world population) lung cancer mortality rates per 100 000 women and joinpoint analysis (1965–2001), at all ages,
truncated at 35–64 years and at 20–44 years in the European Union
Age-standardized mortality rates Jointpoint analysis
1965 2001 Trend 1 Trend 2 Trend 3
Years EAPC Years EAPC Years EAPC
All ages 5.53 11.16 1965–1971 1.51 1972–1987 2.59a 1988–2001 1.39a
35–64 years 9.15 17.88 1965–1983 2.08a 1984–1997 1.39a 1998–2001 2.93a
20–44 years 1.19 1.59 1965–1969 0.84a 1970–1997 2.78a 1998–2001 3.60a
aSignificantly different from 0 (P <0.05).
EAPC, estimated annual percent of change.
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Figure 3. Jointpoint analysis for female lung cancer mortality in the
European Union, 1965–2001. (A) All ages, squares; truncated at
35–64 years, circles. (B) Age 20–44 years.
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